
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

CalciMedica, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

505 Coast Boulevard South, Suite 300-9
La Jolla, California
(Address of Principal Executive Offices)

45-2120079
(I.R.S. Employer
Identification No.)

92037
(Zip Code)

2023 Equity Incentive Plan
2023 Employee Stock Purchase Plan
(Full titles of the plans)

A. Rachel Leheny, Ph.D.
Chief Executive Officer
505 Coast Boulevard South, Suite 300-9
La Jolla, California 92037
(858) 952-5500
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Thomas A. Coll
Carlos Ramirez
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000

John M. Dunn
General Counsel
505 Coast Boulevard South, Suite 300-9
La Jolla, California 92037
(858) 952-5500

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐
Non-accelerated filer ☒

Accelerated filer ☐
Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

This Registration Statement on Form S-8 is being filed by CalciMedica, Inc. (the “**Registrant**”) with the Securities and Exchange Commission (the “**SEC**”) for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. The Registrant previously registered its shares of common stock, par value \$0.0001 per share, for issuance under (i) the Registrant’s 2023 Employee Stock Purchase Plan under the Registrant’s Registration Statements on Form S-8 filed with the SEC on [May 12, 2023](#) (File No. 333-271898), [March 28, 2024](#) (File No. 333-278336) and [June 24, 2025](#), as amended [June 27, 2025](#) (File No. 333-288287) (collectively, the “**Registration Statements**”) and (ii) the Registrant’s Amended 2023 Equity Incentive Plan under the Registration Statements and the Registrant’s Registration Statement on Form S-8 filed with the SEC on [August 27, 2024](#) (File No. 333-281800) (together with the Registration Statements, the “**Prior Registration Statements**”). On August 27, 2026 the Company effected a reverse stock split of its outstanding shares of Common Stock at a ratio of 1-for-5 (the “**Reverse Stock Split**”). The number of shares of Common Stock registered hereby gives effect to the Reverse Stock Split and the shares of Common Stock registered by the Prior Registration Statements have been automatically adjusted to give effect to the Reverse Stock Split; however such Prior Registration Statements and any documents incorporated by reference herein and therein, except as otherwise stated, have not been amended to reflect such automatic adjustment or the Reverse Stock Split. Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

ITEM 8. EXHIBITS.

Exhibit Number	Description
4.1	Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
4.2	Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
4.3	Certificate of Amendment to Amended and Restated Certificate of Incorporation of CalciMedica, Inc., effective August 28, 2026 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 27, 2026).
4.4	Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020).
5.1	Opinion of Cooley LLP.
23.1	Consent of Independent Registered Public Accounting Firm.
23.2	Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1	Power of Attorney. Reference is made to the signature page hereto.
99.1	CalciMedica, Inc. Amended 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 20, 2026).
99.2	Form of Option Grant Notice and Option Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
99.3	Forms of Restricted Stock Unit Grant Notice and Unit Award Agreement under CalciMedica, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K, filed with the SEC on March 22, 2023).
99.4	CalciMedica, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.9 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on May 12, 2023).
107	Filing Fee Table.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of La Jolla, State of California, on September 23, 2026.

CALCIMEDICA, INC.

By: /s/ A. Rachel Leheny, Ph.D.

A. Rachel Leheny, Ph.D.

Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints A. Rachel Leheny, Ph.D. and Stephen Bardin, and each of them, as true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in their names and behalf in their capacities as officers and directors to enable CalciMedica, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/S/ A. RACHEL LEHENY, PH.D. A. Rachel Leheny, Ph.D.	Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	September 23, 2026
/S/ STEPHEN BARDIN, M.B.A. Stephen Bardin, MBA	Chief Financial Officer <i>(Principal Financial and Accounting Officer)</i>	September 23, 2026
/S/ ROBERT N. WILSON Robert N. Wilson	Chairman	September 23, 2026
/S/ ALAN GLICKLICH, M.B.A. Alan Glicklich, M.D., M.B.A.	Director	September 23, 2026
/S/ FREDERIC GUERARD, PHARM.D. Frederic Guerard, Pharm.D.	Director	September 23, 2026
/S/ ALLAN SHAW Allan Shaw	Director	September 23, 2026
/s/ EVGENY ZAYTSEV Evgeny Zaytsev, M.D., Ph.D.	Director	September 23, 2026



Carlos Ramirez
T: +1 858 550 6157
cramirez@cooley.com

September 23, 2026

CalciMedica, Inc.
505 Coast Boulevard South, Suite 300-9
La Jolla, CA 92037

Ladies and Gentlemen:

We have acted as counsel to CalciMedica, Inc., a Delaware corporation (the “**Company**”), in connection with the filing by the Company of a registration statement on Form S-8 (the “**Registration Statement**”) with the Securities and Exchange Commission (the “**Commission**”), covering the offering of up to 1,685,248 shares of the Company’s Common Stock, \$0.0001 par value per share (the “**Shares**”), consisting of (i) 1,654,374 shares issuable pursuant to the Company’s 2023 Equity Incentive Plan, as amended (the “**2023 Plan**”), and (ii) 30,874 shares issuable pursuant to the Company’s 2023 Employee Stock Purchase Plan (together with the 2023 Plan, the “**Plans**”).

In connection with this opinion, we have examined and relied upon (i) the Registration Statement and related prospectuses, (ii) the Company’s certificate of incorporation and bylaws, each as currently in effect, (iii) the Plans, and (iv) such other records, documents, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents by all persons other than by the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Cooley LLP 10265 Science Center Drive San Diego, CA 92121
t: (858) 550-6000 f: (858) 550-6420 cooley.com



Page Two

Sincerely,

Cooley LLP

By: /s/ Carlos A. Ramirez

Carlos A. Ramirez

Cooley LLP 10265 Science Center Drive San Diego, CA 92121
t: (858) 550-6000 f: (858) 550-6420 cooley.com

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in this Registration Statement on Form S-8 of CalciMedica, Inc. (the “Company”) of our report dated March 3, 2026, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern uncertainty), appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Baker Tilly US, LLP

San Diego, California
September 23, 2026

Calculation of Filing Fee Tables

S-8

CalciMedica, Inc.

Table 1: Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
1	Equity	Common Stock, \$0.0001 par value per share, reserved for issuance pursuant to the 2023 Equity Incentive Plan	Other	1,654,374	\$ 1.91	\$ 3,159,854.34	0.0001381	\$ 436.38
2	Equity	Common Stock, \$0.0001 par value per share, reserved for issuance pursuant to the 2023 Employee Stock Purchase Plan	Other	30,874	\$ 1.91	\$ 58,969.34	0.0001381	\$ 8.14
Total Offering Amounts:						\$ 3,218,823.68		\$ 444.52
Total Fee Offsets:								\$ 0.00
Net Fee Due:								\$ 444.52

Offering Note

¹ The amount registered represents (i) an additional 1,500,000 shares of Common Stock ("Common Stock") of CalciMedica, Inc. (the "Registrant") authorized for issuance under the 2023 Equity Incentive Plan (the "2023 Plan") pursuant to an amendment to such plan that was approved by the Registrant's stockholders on August 19, 2026 and (ii) 154,374 shares of Common Stock that were automatically added to the shares authorized for issuance under the 2023 Plan on January 1, 2026, after giving effect to the 1-to-5 reverse stock split effected by the Registrant on August 27, 2026 (the "Reverse Stock Split"), pursuant to an "evergreen" provision contained in the 2023 Plan. Pursuant to such provision, on January 1st of each year through (and including) January 1, 2033, the number of shares authorized for issuance under the 2023 Plan will be automatically increased by the lesser of (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year or (b) such lesser number of shares of Common Stock as the Registrant's board of directors (the "Board") may designate prior to the applicable January 1st. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the 2023 Plan by reason of any stock dividend, stock split, recapitalization or other similar transaction. The proposed maximum offering price per share and maximum aggregate offering price are estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule

